Biosimilars 101: considerations for U.S. oncologists in clinical practice-Reference-Cited by-同舟云学术

Biosimilars 101: considerations for U.S. oncologists in clinical practice

Published:2014-05-09 Issue:4 Volume:3 Page:889-899
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Med

Author:

Camacho Luis H.¹,Frost Craig P.²,Abella Esteban³,Morrow Phuong K.³,Whittaker Sadie³

Affiliation:

1. St. Luke's Hospital Cancer Center Houston Texas

2. St. Luke's Episcopal Hospital Pharmacy and Oncology Service Line Houston Texas

3. Amgen Inc. Thousand Oaks California

Funder

Amgen

Publisher

Wiley

Subject

Cancer Research,Radiology Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.258

Reference51 articles.

2. Developing the Nation's Biosimilars Program

3. IMS Health.Shaping the biosimilars opportunity: a global perspective on the evolving biosimilars landscape.IMS Health. Available at:http://www.imshealth.com/ims/Global/Content/Home%20Page%20Content/IMS%20News/Biosimilars_Whitepaper.pdf(accessed 21 October 2013).

4. Biologicals and biosimilars: a review of the science and its implications

5. Comparability and biosimilarity: considerations for the healthcare provider

Cited by 45 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

2. Biosimilars in Gastric Cancer;Biosimilars for Cancer Treatment;2024

3. Mechanism of Biosimilars for the Treatment of Cancer;Biosimilars for Cancer Treatment;2024

4. Pharmaceutical and Biopharmaceutical Industries: Revolutionizing Healthcare;Archives of Pharmacy and Pharmaceutical Sciences;2023

5. Oncology biosimilars: New developments and future directions;Cancer Reports;2022-10-04